ARTICLE | Politics, Policy & Law
Pfizer MFN deal changes nothing and everything
While the pharma emerged unscathed, its deal with the White House has created a precedent for presidents to negotiate drug pricing
October 3, 2025 10:54 PM UTC
Pfizer’s “most favored nation” drug pricing deal with the Trump administration and the deals with Lilly, Regeneron and other companies that will be announced in the coming weeks have irrevocably altered the pharmaceutical industry’s relationship with the U.S. government.
The short-term consequences for Pfizer Inc. (NYSE:PFE) are negligible. The immediate costs to other pharmas will vary, depending on their exposure to Medicaid and ability to invest in U.S.-based manufacturing. ...